Specialists in

Developing and Commercializing

Infectious Disease Medicines

CORPORATE PRESENTATION – OCTOBER 27, 2023

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 1

DISCLAIMER & FORWARD-LOOKING STATEMENTS
DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the
“Company”) and does not purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties will be expected
to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment in the Company. The Company makes no representation or
warrant as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or
for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation
and contents herein are the exclusive property of the Companyand maynot be copied without the express prior written consent of the Company.
FORWARD LOOKING STATEMENTS. This communication includes forward-looking statements based on the Company’s current expectations and projections about future events. All
statements contained in this communication other than statements of historical fact, including anystatements regarding our future operations, are forward-looking statements. The
words “believe”, “may”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “could”, “would”, “project”, “plan”, “potentially”, “likely” and similar expressions are intended
to identify forward-looking statements as defined in the Private securities Litigation ReformAct of 1995.
The forward-looking statements contained in this communication are based on knowledge of the environment in which the Company currently operates and are subject to
changed based on various important factors that may affect the Company’s operations, growth strategies, financial results and cash flows, and as well as other factors beyond the
Company’s control as of the date of this presentation.
Important factors that could cause our actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others, the
following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax
rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for Tafenoquine (Arakoda
or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we cannot guarantee our ability to conducted successful clinical trials;
and we have no manufacturing capacity which pits at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-k and our subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s
website at www.sec.gov. As a result of these matters, changes in fact, assumptions not being realized or other circumstances, the Company’s actual results may differ materially
from the expected results discussed in the forward-looking statements contained in this presentation.
In light of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements, which speak only as of the date of this
presentation. Although we believe our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Unless required by law,
we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 2

Overview
60 Degrees Pharmaceuticals, a growth-oriented biotech
company, specializes in the development and
commercialization of new therapies used to treat and
prevent serious infectious diseases.
Cutting-edge biological science and applied research form
the foundation of our highly-focused, advanced clinical
strategy.
In 2019, 60P's malaria prevention product,
ARAKODA® (tafenoquine), was made commercially
available after receipt of U.S. regulatory approval in 2018.
Our current product development targets include tick-
borne, viral, fungal and other serious infectious diseases
with unmet needs we perceive in the marketplace.

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 3

About ARAKODA® [tafenoquine succinate]
■ Developed by US Army as a prophylactic antimalarial (through 2013)

■ 60P and USAMMDA formed a partnership in 2014:

■ FDA approval in 2018 [for malaria prevention]
■ Commercially available in U.S. from Q3 2019

■ Dosing & Duration of Use

■ Load: 200 mg/day x 3 days

■ Maintenance: 200 mg once per week

■ Safety Profile
■ 8 published clinical studies involving > 1,100 patients
■ Overall adverse event rate of tafenoquine 200 mg weekly for 52 weeks is comparable to placebo.
■ G6PD screening required prior to use

■ See paper in Travel Medicine & Infectious Disease [Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen: A 12-month, randomized,
double-blind, placebo-controlled trial - ScienceDirect]

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 4

 B– Yeasts& Fungi2
Tafenoquine – Potential Use
in Multiple Indications
A– Malaria1

C-COVID-193 D – Babesiosis4

1. M cCarthy et al. CID 2019;69:480-486. 2. Dow & Smith. New

M icrobes New Infections; doi: 10.1016/j.nmni.2022.100964. 3..
Unpublished data from NCT0453347. 4. Rogers et al CID 2022; doi:
©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 5
10.1093/cid/ciac473.
•.

Babesiosis Patient Volume and Standard of Care (First Cut)

■ At risk populations are potentially large but poorly defined in medical literature
■ Standard of care treatment regimens for babesiosis are long, complicated, or don’t exist
Potential Indications Potential Existing Standard of Care
Patient/Prescription
Volume
Babesiosis – Treatment
Immunosuppressed < 1,400* First Line: Azithromycin + atovaquone for 10 days or > 6 weeks if
Hospitalized Up to 1,400* immunosuppressed**
Outpatient Up to 38,000*
Babesiosis – Prevention
Post Exposure (tick bites) Up to 400,000*** Insect repellents, protective clothing
Pre-Exposure Up to 1.2 million #
Chronic Tick-Borne Diseases
Babesiosis Unknown No specific FDA-approved treatments
PTLDS(new/cumulative through 2020) Up to 100,000/1,9000,000&
* Total babesiosis patients in U.S. may be approximately 47,000 per year based on the observation that there are 476,000 lyme infections each year, 10% of which are
also babesiosis coinfections (Krause et al JAMA 1996;275:1657-16602. Krugeler et al Emerg Infect Dis 2021;27:616-61). Approximately 80% of adult babesiosis infections
are symptomatic, yielding a treatable patient pool of about 38,000. There are up to 1,400 hospitalized cases per year in the U.S (Bloch et al 2022 Nov
8;9( 11):ofac597. doi: 10.1093/ofid/ofac597. eCollection 2022 Nov.), an unknown (i.e. < 1,400) number of of which represent immunosuppressed patients. ** According to
IDSA guidelines.*** Based on the observation that 50,000 tick bites are treated in USemergency rooms each year, representing about 12% of the total number (Marx et.
al., MMWR 2021;70:612-616) # Determined on a pro rata basis using company estimates of malaria market as being 550,000 three-week prescription per year
amongst an at-risk travel population of ~ 10 million, versus a seasonally adjusted at-risk population for B. microti infection in the U.S. of ~ 22.5 million. &Cumulative
incidence in U.S. in 2020. elonget al. 2019 Apr 24;19(1):352. doi: 10.1186/s12889-019-6681-9.

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 6

Portfolio PHASES AND DEVELOPMENT STAGES

PHASE III and/or COMMERCIALLY

PHASE 1 PHASE IIA PHASE IIB AVAILABLE IN
REGULATORY REVIEW
U.S.

ARAKODA® - MALARIA PREVENTION Q3 2019*

Tafenoquine: Phase IIB/IIII treatment study

Babesiosis of tafenoquine in babesiosis
treatment patients
Interim data Q4-24 = Completed
= Next phase

ACLR8-LR*** SUSPENDED
Tafenoquine (ARAKODA regimen): PENDING ASSESSMENT OF
COVID-19 INDICATIONS FEASIBILITY OF CONDUCTING
EX U.S.

Tafenoquine: NOTES:
Candidiasis & *ARAKODA® is commercially available in the U.S. for malaria prevention and will be the subject of targeted marketing
fungal
efforts in 2023 and 2024, supported by the hiring of a commercial operations executive (pending). **Existing funds will
pneumonias#
support achieving FDA clearance, but execution of the Phase IIB/III treatment study will require additional funds. ***
ACLR8-LR was to evaluate the ARAKODA regimen of tafenoquine as a potential COVID-19 therapeutic in patients with
low risk of disease progression but has been suspended following advice from FDA suggesting its execution in the U.S.
Celgosivir:
was unfeasible. The Company may revisit this in the future of a low-cost Phase IIB study could be performed in an ex U.S.
Respiratory jurisdiction. #Both these products have been the subject of clinical studies for other indications. Additional non-clinical
viruses & efficacy and mechanism of action studies are required before committing to further clinical development. These activities
dengue# will be conducted in 2023 only if resources permit. ## Protocol on clinicaltrials.gov will be updated when revised IND
submitted to FDA. Timelines assume IND resubmission in Q4 2023.

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 7

Babesiosis Clinical Development Plan (Proposed to FDA)

Phase IIB/III
Low Risk
Seek FDA Hospitalized Patients
File sNDA
clearance/Type C Summer 2024
[If FDA
Meeting
TQ + SOC v Placebo + SOC concurs]
Q4 2023
Proposed 20 Patients
Endpoint: Time To Molecular Clearance (TTMC- time to first of two consecutive
negative PCRs)

Compassionate Use IND

High Risk
Hospitalized Patients
Summer 2024

Open Label Tafenoquine:

TBD Load then weekly dosing until TTMC

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved.

Commercial Infrastructure & Supply Chain

API& Tablets Packaging 3PLTitle Model Distributors

PBMs
Various

Piramal,India PCI, Philadelphia,U.S. ICS,BrooksKY,USA ASB,Two Other U.S.

Prime Vendors

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 9

Intellectual Property & Licensing
60 Degrees Pharmaceuticals has freedom to operate

■ U.S. Arakoda Patents (2 issued/6 in progress)

■ Tafenoquine for malaria prevention patent family: Earliest expiration December 2034 Existing License & Distribution Agreements
■ Tafenoquine for lung Infections/COVID Treatment: Earliest expiration March 2041 [Malaria]

Territory Partner
■ U.S. Celgosivir Patents Europe Scandinavian Biopharma
■ Dengue/RSV (4 issued/2 in progress) Australia, NZ, Pacific Biocelect
■ COVID-19 licensed from FSU (1 issued/1 in progress)
Islands
Canada, Latin America, Knight Therapeutics
Israel, Russia
■ International Patents
■ 6/2 for Celgosivir issued/in progress, 1/8 for tafenoquine issued/in progress

■ Clinical, non-clinical and manufacturing information:

■ Worldwide rights for all indications [except P. vivax malaria] licensed from US Army

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 10

Key Achievements & Milestones
NDA filed and
ARAKODA Tafenoquine
Company First Institutional approved by FDA COVID-19 patents COVID-19 patent
Founded Financing & TGA filed issued

2010 2015 2018 2020 2023

2014 / 15 2017 2019 2021 2023

Research and licensing TafenoquineIND filed ARAKODA enters Key clinical studies IPO on NASDAQ
agreement for First clinical trial(s) USsupply chain, completed:
tafenoquine (ARAKODA) completed commercial - Long term safety
signed with USArmy infrastructure - COVID-19Phase IIA
established

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 11

 Anticipated Future Milestones (Babesiosis Phase IIB/III)

Last Patient Out

Seek Type CMeeting Clearance to Proceed Unblinding

BabesiosisPhase Q42023 Q12024 Q42024

IIB/III Milestones Q1 2024 Q3 2024 Q12025

Submit protocol First Patient In Study

against malaria IND Completion – File
sNDA?

OTHERANTICIPATEDMILESTONES
■ Detailed TAM Estimates for tick-borne diseases ■ Trade & Scientific Conferences

■ Hiring of Chief Commercial Officer ■ Publication on mode of action of tafenoquine

■ New product development collaborations

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 12

Officers & Directors
Cheryl Xu, Director
■ First PhRMA representative to China
Geoffrey Dow MBA PHD, CEO & Chairman
■ Senior Advisor to multinationals (market access and
■ Affiliations: WRAIR, USAMMDA
■ Founded & led 60P from 2010-2023 expansion)
■ Industry Project Leader on Arakoda NDA ■ Project Leader (multiple public health projects)

Stephen Toovey MD, PHD Director

Ty Miller, CFO ■ Affiliations: Roche, Pegasus Research, WHO
■ CPA Collaborating Centre for Vaccines and Travel Medicine,
■ CFO since 2014 London, UK
■ Over 20 years in Private Practice ■ Tropical medicine subject matter expert
■ Respiratory virus subject matter expert
Bryan Smith MD, Chief Medical Officer
Paul Field, Director
■ Retired US Army Colonel/30+ years experience
■ Two successful NDAs as a Chief Medical Officer ■ Affiliations: GARDP, Imunexus, Marinova
■ Medical affairs/regulatory expert in GxP environment ■ 30 years global biotech business development
experience
■ Previously investment specialist at Austrade, focused
on tropical medicine and NTDs
Jenny Herz, Director of 60P Australia since 2013
■ 20 years commercial experience in pharma (Sanofi, AZ) Charles Allen, Director
■ International launch experience with multiple products ■ Affiliations: BTCS & GBV
■ Co-founder of Biointelect and Biocelect ■ CEO & Chairman of NASDAQ listed company
■ Board experience in public, private, NFP sectors ■ Managing Director, several boutique investment banks
■ Broad business experience across multiple sectors

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 13

Investment Highlights
§ ARAKODA – a long-acting, potentially broad-spectrum, anti-infective already FDA-approved for malaria prevention and
commercially available in the U.S.
§ Safe, long acting, mechanistically differentiated antimalarial approved by FDA
§ Discovered by US Army and successfully brought to market by 60P
§ 1,100+ patient exposures in 8+ published clinical trials, weekly dosing for up to one year
§ Commercially available in U.S. via network of major national distributors
§ Existing commercial/regulatory infrastructure expected to facilitate cost-effective pathway to new/expanded indications following targeted clinical trial and label changes

§ Arakoda Regimen of Tafenoquine – Research agenda involving babesiosis and other diseases
§ Malaria, COVID-19, fungal, tick-borne illness of interest to the Company affect millions and are associated with a potentially high revenue unmet medical need
§ Company has strong IP for malaria, COVID-19, and other indications
§ Accelerated clinical recovery from babesiosis is suggested by case studies of immunosuppressed patients administered tafenoquine
§ 2024: Execute Phase IIA treatment study in hospitalized babesiosis patients
§ 2025: sNDA and/or confirmatory babesiosis patient study

§ Experienced management team and Board

§ Team has together led/managed four clinical trials
§ Collectively led multiple pharmaceutical product approvals/product launches
§ Collectively led/provided guidance on 20+ public & private entities
§ Participated in/led multiple public listings

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 14

 Specialistsin
DevelopingandCommercializing
Infectious DiseaseMedicines

Investor Relations Contact

Patrick Gaynes
patrickgaynes@60degrespharma.com
1025 Connecticut Avenue NW 310-989-5666
Suite 1000
Washington, DC 20036

60degreespharma.com

©2023 60 Degrees Pharmaceuticals, INC CONFIDENTIAL All rights reserved. 15